+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Farxiga"

From
From
Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
North America Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

North America Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 89 Pages
  • North America
From
FARXIGA Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

FARXIGA Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Farxiga is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. Farxiga is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Farxiga is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to help regulate hormones and metabolism, and can be taken orally or injected. Companies in the Farxiga market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Show Less Read more